IRMD
IRadimed Corporation · Healthcare · Medical - Devices
Momentum inputs (comparable managers):
holder breadth +14.3% ·
share flow -4.2% ·
net new positions +12.5%
· formula
Ownership fragmentation: more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 82 | -3 | 5.33M | $509.49M | +6 | −9 |
| Q1 2026 | 88 | +3 | 5.07M | $488.33M | +6 | −3 |
| Q4 2025 | 85 | 0 | 4.93M | $479.86M | +1 | −1 |
| Q3 2025 | 16 | +1 | 3.09M | $220.20M | +1 | n/a |
| Q2 2025 | 12 | +2 | 2.63M | $157.45M | +2 | n/a |
| Q1 2025 | 7 | -1 | 1.04M | $54.42M | n/a | −1 |
| Q4 2024 | 8 | +1 | 1.01M | $55.33M | +1 | n/a |
| Q3 2024 | 6 | -3 | 875.49K | $44.03M | n/a | −3 |
| Q2 2024 | 9 | n/a | 935.05K | $41.09M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Renaissance Technologies ✦ | 513.01K | -4.9% | $28.22M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 222.77K | +17.9% | $12.25M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 3 | State Street Global Advisors ✦ (passive) | 174.44K | n/a | $9.59M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Millennium Management ✦ | 44.05K | -45.1% | $2.42M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 5 | Two Sigma Investments ✦ | 18.50K | -54.2% | $1.02M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 6 | AQR Capital Management ✦ | 14.72K | +40.2% | $809,658 | 0.0% | ▲ Add | 3 | SEC ↗ ×3 |
| 7 | D. E. Shaw & Co. ✦ | 13.15K | -17.6% | $723,140 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 5.30K | New | $291,720 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Citadel Advisors | $291,720 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 225 holders, 7.61M shares, $667.38M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 1.01K sh · $87,650
Director · 405 sh · $34,972
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology